These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19436648)

  • 1. Potential of liraglutide in the treatment of patients with type 2 diabetes.
    Deacon CF
    Vasc Health Risk Manag; 2009; 5(1):199-211. PubMed ID: 19436648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Campbell RK
    Ann Pharmacother; 2009 Sep; 43(9):1433-44. PubMed ID: 19638470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide for the treatment of type 2 diabetes: a clinical update.
    Peters KR
    Am J Ther; 2013; 20(2):178-88. PubMed ID: 21734532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide for type 2 diabetes mellitus.
    Kela R; Khunti K; Davies MJ
    Expert Opin Biol Ther; 2011 Jul; 11(7):951-9. PubMed ID: 21563859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
    Mateos JL; Wajchenberg BL
    Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Nishida T; Kaku K
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.
    Kumar A
    Expert Opin Biol Ther; 2014 Jun; 14(6):869-78. PubMed ID: 24702171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
    Bode BW; Brett J; Falahati A; Pratley RE
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].
    Penninga E; Færch K; Almdal T
    Ugeskr Laeger; 2011 Jun; 173(26):1863-9. PubMed ID: 21712007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
    Barnett AH
    Diabetes Obes Metab; 2012 Apr; 14(4):304-14. PubMed ID: 22051096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.